Expanding the Toolkit for Fighting Solid Tumors

9:00 AM - 9:55 AM, Monday, February 10, 2020 ・ Lyceum Complex
As PD-1/L1 checkpoint inhibitors continue to reveal new tumor types those drugs can attack successfully, more than 2,000 combination trials have launched to attempt to enhance those inhibitors’ effects. However, exciting approaches in other mechanisms of action are also expanding our understanding of solid tumors, the tumor microenvironments, and the opportunities to disrupt tumor growth and help cancer patients. This panel will explore the breadth of the tumor-fighting pipelines and those clinical benefits likely to be realized soonest.
Moderator
photo
Managing Director, Senior Biotechnology Analyst
SunTrust Robinson Humphrey
Speakers
photo
President and CEO
ImmunoMet Therapeutics
photo
Chief Executive Officer
OncoSec Immunotherapies
photo
Chief Medical Officer
Harpoon Therapeutics
photo
CEO and President
TriSalus Life Sciences
photo
Chief Medical Officer
Nektar Therapeutics